Congress and the Trump administration are riled up about pharma prices and promising to drive them down, but a new U.S. government report shows growth in retail drug spending screeched to a halt in 2017.
The data, released by the Centers for Medicare & Medicaid Services Thursday, show growth in spending on pharmacy-dispensed drugs slowed to 0.4% last year, down sharply from 2.3% in 2016—and even more sharply from the increases in 2015 and 2014, CMS reported. Drug costs for those years grew 8.9% and 12.4%, respectively.
Why the slowdown? For one thing, drugmakers pushed through lower price hikes, CMS said. Prescription growth also slowed, while more patients started on generics and generic prices dropped, the agency said.
The new CMS data hit as drug prices continue to occupy center stage in Washington. After years of scrutiny on pharma’s pricing practices—and annual increases in prices and costs—Congress and the Trump administration have made the issue a priority. The FDA is approving generics at a record pace and prioritizing applications for drugs with little to no competition. The administration is working to force drugmakers to include prices in TV ads and lower certain U.S. prices closer to international levels, among a slew of other proposals.
Meanwhile, uncomfortable in the spotlight, many drugmakers have pumped the brakes on price hikes. Pfizer, for instance, raised prices this summer but backpedaled—at least temporarily—after the president slammed the company on Twitter. Trump tweeted that Pfizer “should be ashamed” about the move, and the company decided to defer price hikes. It now appears ready to raise them again in early 2019.
During the Pfizer controversy, other large drugmakers such as Novartis and Roche said they wouldn’t raise prices again in 2018.
By Eric Sagonowsky
Source: Fierce Pharma
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
